{Reference Type}: Journal Article
{Title}: Two cases of typical HUS in adults treated with an anti-C5 monoclonal antibody: a new perspective?
{Author}: Stambolliu E;Giannou P;Nomikou E;Aggelis G;Petras D;
{Journal}: J Nephrol
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 29
{Factor}: 4.393
{DOI}: 10.1007/s40620-024-02034-2
{Abstract}: Hemolytic uremic syndrome (HUS) is a rare clinical entity, especially in adults. In its typical form the causative factor that triggers the cascade of immunologic and inflammatory events is a Shiga toxin-producing pathogen, found in the patient's stool. Renal and neurologic involvement usually prevails and requires immediate care. Regarding this potentially life-threatening condition, little is known and the mainstay is supportive care. However, some interesting evidence has come up about the use of eculizumab, an anti-C5 monoclonal antibody, mainly in pediatric patients with typical HUS. Herein, we present two cases with typical HUS caused by two different strains of Escherichia coli (Shiga toxin-producing enterohemorrhagic and enteropathogenic) who were both treated effectively with anti-C5 monoclonal antibodies (eculizumab and ravulizumab).